In contrast, in the CDDP+rEndo (10 μg/mL)-treated cells, the mean percentage of CD90+ cells did not change significantly (Figure 2C), suggesting that rHGFK1 and the rHGFK1+ rEndo could synergistically enhance the chemotherapy sensitivity and inhibit the self-renewal ability of the CD90+ CSCs of HCC cells. Here, THY1 is linked to hepatocellular carcinoma.